drugset / Trial / NCT00796991

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

NCT00796991

Phase 1 Completed 72 enrolled Bristol-Myers Squibb Medarex · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine

Timeline

Start
2009-02
Primary completion
2009-11
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 6 unknown Intravenous
Comparator Dacarbazine Small molecule 850 mg/m2 Intravenous
Comparator Ipilimumab Monoclonal antibody 10 mg/kg Intravenous
Comparator Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications